Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Gain the latest insights on respiratory infections and related rapid tests aimed at expediting appropriate isolation decisions and antiviral treatments. Be informed on the technology differences in diagnostic test methods and hear use cases on testing protocols focused on efficient patient management and quality initiatives, including antimicrobial stewardship.
Respiratory Season: New Diagnostic Challenges and Strategies for Antimicrobial Stewardship
Die chronische Nierenerkrankung (CKD) ist durch einen progressiven, schleichenden Verlauf gekennzeichnet, was ein aktives Monitoring sehr wichtig macht.
The diagnosis moment: – the role of POCT HbA1c in undiagnosed diabetes and prediabetes in plowing the progression of diabetes and improving health equ...
This webinar will discuss screening for and prevention of chronic disease in severe mental illness (SMI) patients and patients with learning disabilities (LD).
The value of POCT in SMI health checks and patients with learning disabilities for the diagnosis, management and monitoring of diabetes and cardiovasc...
In this new webinar session, Doctor Nguyen explores the impact of the implementation of rapid molecular biology tests in the emergency department and the impact on patients care management within the emergency room.
Clinical and operational impact of rapid point-of-care SARS-COV-2 detection in an emergency department
Faster and more effectivetechnology advances diagnostic testing within the walls of the central lab and indecentralized, near-patient settings. Explore the future of the lab and gain experts’insights on the broadened scope of the lab with test methods that provide qualityinformation supporting clinical needs and decision making.
The lab of the future: How COVID-19 taught us the value of transcendent laboratory service
Omicron globally became the predominant SARS-CoV-2 variant in late 2021. Some studies have suggested Omicron has a different replication pattern that could affect detection by rapid antigen tests. Reports in social media have promulgated oral swabs as a superior sample for detecting Omicron in the early stage of infection compared to nasal swabs.
Transitioning to Endemic COVID-19 Testing: Evidence-Based Assessment on Current and Future Rapid Antigen Test Detection
The webinar was an opportunity to share the success of HIV POC EID & VL monitoring in Mozambique and Cameroon to a larger audience and allow key stakeholders to be informed on the benefits of m-PIMA as a critical tool in reaching HIV targets.
The implementation of LF-LAM in patients with advanced HIV disease has showed promise as a simple, inexpensive POC platform. The webinar serves to provide insight into practical implementation of LF-LAM and demonstrate the successful integration in the South African context.
The importance of LF-LAM technology in TB diagnosis among patients with advanced HIV diagnosis
Join this global webinar for real-world case reports on new and breakthrough infections and practical strategies being implemented in the pediatric and adult settings that help facilitate optimal care and workflow in time sensitive care settings.
COVID-19 co-infections: best practices for rapid differential diagnosis in pediatrics and adults
One-size does not fit all across today's diverse and dynamic test settings. From antigen to molecular tests and various use cases, rapid test methods offer unique and overlapping utility, advantages, and disadvantages.
Expert perspectives on rapid point-of-care testing for respiratory infections
On the threshold of the 2021-2022 respiratory season, this timely update centers on influenza A&B, the COVID-19 pandemic and steps healthcare systems are taking to prepare for the upcoming (and uncertain) respiratory season
The unpredictable respiratory season: influenza and COVID-19
Join this interactive discussion on how the different adoption of C-reactive protein point-of-care testing in different countries has influenced and could influence antibiotic misuse and antimicrobial resistance rates.
Fighting forwards: how to keep antibiotics working in an age of resistance
Cardiovascular diseases are a leading cause of death globally, taking 17.9 million lives each year1. Patients at risk of cardiovascular disease (CVD) may show raised blood pressure, have diabetes or have high lipid levels. The good news is, reducing the risk of cardiovascular disease (such as dyslipidemia, hypercholesterolemia and hypertriglyceridemia) is possible with lipid panel tests to identify risk, and continued testing for monitoring.
A one stop shop: the impact of point-of-care lipid testing on cardiovascular disease screening and management
Join this session to learn from experts in cardiovascular disease prevention about the recent evidence on risk stratification, to get insights from their daily clinical practice and to learn how to use cardiac biomarkers and lipid profile in a more efficient way
Cardiovascular risk assessment and prevention: where do we stand?
Join our panel of experts from around the world to learn about Chronic disease management in the post COVID era - the value of point of care testing for cardiovascular risk and kidney disease management in diabetes and non diabetes patients. The webinar will analyse studies and present front line experience on the value of point of care testing told through the eyes of internationally acclaimed health care professionals and academics from Germany...
Chronic disease management in the post COVID era - the value of point of care testing for cardiovascular risk and kidney disease management in diabete...
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Should you screen for kidney damage? What do the guidelines say?
Chronic kidney disease is a common and often silent condition – up to one in ten adults could be affected in Europe, Canada and Israel, yet only one-third of these will have had a diagnosis1.
Impact of ACR POC testing on the diagnosis and management of diabetic kidney disease
en
今すぐアクセス
これ以上の結果はありません
By using this site, you agree with our use of cookies.
